Automated determination of dextromethorphan and its main metabolites in human plasma by high-performance liquid chromatography and column switching

Therapeutic Drug Monitoring

Volumn 18, Issue 3, 1996, Pages 297-303

  Hartter S ^a   Baier, D ^b   Dingemanse, J ^c   Ziegler, G ^d   Hiemke, C ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b ROCHE INNOVATION CENTER MUNICH   (Germany)

^c Hoffmann La Roche ^*  (Switzerland)

^d Institute of Psychosomatic Research   (Germany)

Author keywords

Column switching; Dextromethorphan; Dextrorphan; High performance liquid chromatography; Pharmacogenetics

Indexed keywords

DEXTROMETHORPHAN; DEXTRORPHAN; MORPHINAN DERIVATIVE;

ADULT; ARTICLE; COUGHING; DIAGNOSTIC ACCURACY; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; ANTITUSSIVE AGENTS; BIOTRANSFORMATION; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; FEMALE; HUMANS; MALE; PHENOTYPE; QUALITY CONTROL; REGRESSION ANALYSIS; SPECTROMETRY, FLUORESCENCE;

EID: 0029941721     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199606000-00014     Document Type: Article

References (25)

1. Tortella FC, Pellicano M, Bowery NG. Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends Pharmacol Sci 1989;10:501-7.
2. Gorski JC, Jones DR, Wrighton SA, et al. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994;48:173-82.
3. Tucker GT. Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol 1994;46(suppl 1):417-24.
4. Birkett DJ, Mackenzie PI, Veronese ME, et al. In vitro approaches can predit human drug metabolism. Trends Pharmacol Sci 1993;14:292-4.
5. Meyer UA. The molecular basis of genetic polymorphism of drug metabolism. J Pharm Pharmacol 1994;46(suppl 1):409-15.
6. Hildebrand M, Seifert W, Reichenberger A. Determination of dextromethorphan metabolizer phenotype in healthy volunteers. Eur J Clin Pharmacol 1989;36:315-18.
7. Baumann P, Meyer JW, Amey M, et al. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther Drug Monit 1992;14:1-8.
8. Relling MV, Cherrie J, Schell MJ, et al. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther 1991;50:309-13.
9. Yue QY, Bertilsson L, Säwe J, et al. Interethnic differences in drug oxidation. Neuropsychopharmacology 1994;10(3S): 489S.
10. Gonzales FJ, Meyer UA. Molecular genetics of the debrisoquin-sparteine polymorphism. Clin Pharmacol Ther 1991;50: 233-7.
11. Sjöqvist F, Bertilsson L. Clinical pharmacology of antidepressant drugs: pharmacogenetics. In: Usdin E, Åsberg M, Bertilsson L, Sjöqvist F, eds. Frontiers in biochemical and pharmacological research in depression. New York: Raven Press, 1984:359-71. (Advances in biochemical psychopharmacology; vol 39).
12. Sjöqvist F, Bertilsson L. Clinical pharmacology of antidepressant drugs: pharmacogenetics. In: Usdin E, Åsberg M, Bertilsson L, Sjöqvist F, eds. Frontiers in biochemical and pharmacological research in depression. New York: Raven Press, 1984:359-71. (Advances in biochemical psychopharmacology; vol 39).
13. Baumann P, Jonzier-Perey M. GC and GC-MS procedures for simultaneous phenotyping with dextromethorphan and mephenytoin. Clin Chim Acta 1988;171:211-22.
14. Park YH, Kullberg MP, Hinsvark ON. Quantitative determination of dextromethorphan and three metabolites in urine by reversed-phase high-performance liquid chromatography. J Pharm Sci 1984;73:24-9.
15. De Zeeuw RA, Eikema D, Franke JP, et al. A rapid thin layer chromatographic procedure to identify poor and extensive oxidative metabolizers in man using dextromethorphan. Pharmazie 1992;47:346-8.
16. Evans WE, Relling MV. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. Pharmacogenetics 1991;1:143-8.
17. Funck-Brentano C, Thomas G, Jacqz-Aigrain E, et al. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. J Pharmacol Exp Ther 1992; 263:780-6.
18. Mura C, Panserat S, Vincent-Viry M, et al. DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers. Hum Genet 1993; 92:167-72.
19. Johansson M, Svensson C. Determination of dextromethorphan and its metabolites in plasma by dual column liquid chromatography and fluorometric detection. J Pharm Biomed Anal 1988;6:211-20.
20. Chen ZR, Somogyi AA, Bochner F. Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Ther Drug Monit 1990;12:97-104.
21. East T, Dye D. Determination of dextromethorphan and metabolites in human plasma and urine by high-performance liquid chromatography with fluorescence detection. J Chromatogr Biomed Appl 1985;338:99-112.
22. Schmid B, Bircher J, Preisig R, et al. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther 1985;38:618-24.
23. Dayer P, Balant L, Courvoisier F, et al. The genetic control of vufuralol metabolism in man. J Drug Metab Pharmacokin 1982;7:73-7.
24. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. CYP2D6-and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 1993;3:197-204.
25. Coutts RT, Su P, Baker GB. Involvement of CYP2D6, CYP3A4, and other cytochrome P-450 isoenzymes in N-dealkylation reactions. J Pharmacol Toxicol Meth 1994; 3:177-86.